Previous 10 | Next 10 |
The recent unsolicited licensing offer is likely United Therapeutics, which has several compelling reasons to want to own Liquidia and could pay a large premium to block the RareGen merger. If a near term deal with United Therapeutics does not come to fruition (it would have to occur ...
MannKind Corporation is a biopharma company focused on developing and commercializing inhaled therapeutics for endocrinology and lung diseases. Mannkind has one FDA-approved inhalable insulin formulation, Afrezza (launched 2015), undergoing a turnaround global-marketing strategy and i...
United Therapeutics Corporation To Present At The Credit Suisse 29th Annual Virtual Healthcare Conference PR Newswire SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 2, 2020 SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Nov. 2, 2020 /PRN...
United Therapeutics Corporation (UTHR) Q3 2020 Earnings Conference Call October 28, 2020 09:00 ET Corporate Participants Dewey Steadman - Head, Investor Relations Martine Rothblatt - Chairman & Chief Executive Officer Michael Benkowitz - President & Chief Operating Officer Leigh Peter...
Image source: The Motley Fool. United Therapeutics Corp (NASDAQ: UTHR) Q3 2020 Earnings Call Oct 28, 2020 , 9:00 a.m. ET Operator Continue reading For further details see: United Therapeutics Corp (UTHR) Q3 2020 Earnings Call Transcript ...
United Therapeutics (UTHR) Q3 results:Revenues: $380.1M (-5.3%) vs consensus of $357.95Mb.Key product sales: Remodulin: $124.5M (-26%); Tyvaso: $129.5M (+17%); Orenitram: $74.7M (+20%); Unituxin: $37.6M (+25%); Adcirca: $13.8M (-54%).Net Income: $171.2M (+29%); EPS: $3.84 (+28%); non-GAA...
United Therapeutics (UTHR): Q3 Non-GAAP EPS of $3.88 beats by $0.54; GAAP EPS of $3.84 beats by $1.16.Revenue of $380.1M (-5.3% Y/Y) beats by $22.15M.Press Release For further details see: United Therapeutics EPS beats by $0.54, beats on revenue
United Therapeutics Corporation Reports Third Quarter 2020 Financial Results - Third quarter Orenitram® net revenue growth of 20% and Tyvaso® net revenue growth of 17% year-over-year - Remodulin® sequential quarterly net revenue growth of 5% - INCREASE sND...
United Therapeutics (NASDAQ:UTHR) is scheduled to announce Q3 earnings results on Wednesday, October 28th, before market open.The consensus EPS Estimate is $3.34 (-12.8% Y/Y) and the consensus Revenue Estimate is $357.95M (-10.8% Y/Y).Over the last 2 years, UTHR has beaten EPS estimates 88% o...
United Therapeutics Highlights Poster Presentations from the Recent CHEST 2020 Meeting Clinical study data suggests Tyvaso® improved forced vital capacity, an important measure of lung function, in patients with pulmonary hypertension associated with interstitial lung disea...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...